Qian Qin, MD, outlines trial of neoadjuvant zanzalintinib plus nivolumab in ccRCC

In an interview at the 2025 European Society for Medical Oncology Congress in Berlin, Germany, Qian Qin, MD, outlined the background and design of the phase 2 EXPLORE-RCC trial (NCT06794229), evaluating the combination of zanzalintinib plus nivolumab (Opdivo) in patients with locally advanced and/or inoperable clear cell renal cell carcinoma.¹ Qin is an assistant professor of internal medicine at UT Southwestern Medical Center in Dallas, Texas.

REFERENCE

1. Qin W, Zhang S, Brugarolas J, et al. EXPLORE-RCC: A phase II study of neoadjuvant zanzalintinib (ZANZA) plus nivolumab (NIVO) in patients with locally advanced and/or inoperable clear cell renal cell carcinoma (ccRCC). Presented at: 2025 European Society for Medical Oncology Congress. October 17-21, 2025. Berlin, Germany. Abstract 2682eTiP. https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.esmo/static/esmo2025_abstracts/2682eTiP.html.pdf